M. tuberculosis infection
Conditions
Interventions
None listed
Sponsors
Yokohama City University Hospital, Chemotherapy Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: English-language articles that provide data for both sensitivity and specificity of WGS to predict pDST will be included. Sequencing method should be clearly declared as WGS in the article. Conference abstract will be excluded. Data regarding sensitivity and specificity should be clearly presented. A number of isolates should be larger than 20. To avoid duplicate use of the same database, research conducted as consortium and a study using public WGS data repository will be excluded. M. tuberculosis culture isolate and other clinical samples are accepted. All samples should have underwent pDST.
Exclusion criteria
Exclusion criteria: A number of isolates should be larger than 20.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drugs of our interests are isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, amikacin, kanamycin, para-amino-salicylic acid (PAS), capreomycin, levofloxacin, moxifloxacin, ofloxacin, ethionamide, protionamide, and cyclocerine. Combined evaluation of quinolones, first-line drugs, and second-line drugs will not be adopted. Diagnostic odds ratio (DOR), area under the curve (AUC) of summary receiver operating characteristics curve (SROC), estimated sensitivity, and specificity will be calculated. | — |
Countries
Japan
Contacts
Public ContactNobuyuki Horita
Yokohama City University Hospital Chemotherapy Center
Outcome results
None listed